Abstract
The insulinoma-associated 1 (INSM1) gene is expressed exclusively during early embryonal development, but has been found re-expressed at high levels in neuroendocrine tumors. The regulatory region of the INSM1 gene is therefore a potential candidate for regulating expression of a therapeutic gene in transcriptionally targeted cancer gene therapy against neuroendocrine tumors. We analyzed expression of a reporter gene from a 1.7 kb region of the INSM1 promoter in a large number of small-cell lung cancer (SCLC) cell lines. This INSM1 promoter region showed very high levels of expression in most of the SCLC cell lines and expression was absent in cell lines of non-neuroendocrine origin. Inclusion of the general transcriptional enhancer from SV40 compromised the specificity of the promoter and did not enhance transcription in most of the SCLC cell lines. For comparison, the region of the gastrin releasing peptide (GRP) previously suggested for SCLC gene therapy was analyzed in a similar manner. High expression was observed for a number of cell lines, but unlike for the INSM1 promoter, reporter gene expression from the GRP promoter did not correlate to the relative GRP mRNA levels, demonstrating that this region may not contain all necessary regulatory elements. Expression of the suicide gene herpes simplex virus thymidine kinase (HSV-TK) from the INSM1 promoter in combination with treatment with the prodrug ganciclovir (GCV) caused a significant increase in GCV sensitivity specifically in INSM1-expressing cell lines. The INSM1 promoter is therefore a potential novel tool for transcriptionally targeted gene therapy for neuroendocrine tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Simon M, Argiris A, Murren JR . Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004; 49: 119–133.
Turrisi AT, Sherman CA . The treatment of limited small cell lung cancer: a report of the progress made and future prospects. Eur J Cancer 2002; 38: 279–291.
Robson T, Hirst DG . Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003; 2003: 110–137.
Rygaard K, Vindeløv LL, Spang-Thomsen M . Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenografts. Int J Cancer 1993; 54: 144–152.
Nishino K, Osaki T, Kumagai T, Kijima T, Tachibana I, Goto H et al. Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a Myc-Max binding motif. Int J Cancer 2001; 91: 851–856.
Kumagai T, Tanio Y, Osaki T, Hosoe S, Tachibana I, Ueno K et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res 1996; 56: 354–358.
Song JS, Kim HP . Adenovirus-mediated HSV-TK gene therapy using the human telomerase promoter induced apoptosis of small cell lung cancer cell line. Oncol Rep 2004; 12: 443–447.
Coulson JM, Stanley J, Woll PJ . Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer. Br J Cancer 1999; 80: 1935–1944.
Pass MK, Quintini G, Zarn JA, Zimmermann SM, Sigrist JA, Stahel RA . The 5′-flanking region of human CD24 gene has cell-type-specific promoter activity in small-cell lung cancer. Int J Cancer 1998; 78: 496–502.
Tanaka M, Inase N, Miyake S, Yoshizawa Y . Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. Anticancer Res 2001; 21: 291–294.
Miyake Y, Kodama T, Yamaguchi K . Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994; 54: 2136–2140.
Uchida K, Kojima A, Morokawa N, Tanabe O, Anzai C, Kawakami M et al. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. J Cancer Res Clin Oncol 2002; 128: 633–640.
Inase N, Horita K, Tanaka M, Miyake S, Ichioka M, Yoshizawa Y . Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cells. Int J Cancer 2000; 85: 716–719.
Morimoto E, Inase N, Mlyake S, Yoshizawa Y . Adenovirus-mediated suicide gene transfer to small cell lung carcinoma using a tumor-specific promoter. Anticancer Res 2001; 21: 329–331.
Pedersen N, Mortensen S, Sørensen SB, Pedersen MW, Rieneck K, Bovin LF et al. Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res 2003; 63: 1943–1953.
Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790–13795.
Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001; 98: 13784–13789.
Goto Y, De Silva MG, Toscani A, Prabhakar BS, Notkins AL, Lan MS . A novel human insulinoma-associated cDNA, IA-1, encodes a protein with ‘zinc-finger’ DNA-binding motifs. J Biol Chem 1992; 267: 15252–15257.
Lan MS, Russell EK, Lu J, Johnson BE, Notkins AL . IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines. Cancer Res 1993; 53: 4169–4171.
Zhu M, Breslin MB, Lan MS . Expression of a novel zinc-finger cDNA, IA-1, is associated with rat AR42J cells differentiation into insulin-positive cells. Pancreas 2002; 24: 139–145.
Breslin MB, Zhu M, Notkins AL, Lan MS . Neuroendocrine differentiation factor, IA-1, is a transcriptional repressor and contains a specific DNA-binding domain: identification of consensus IA-1 binding sequence. Nucleic Acids Res 2002; 30: 1038–1045.
Xie J, Cai T, Zhang H, Lan MS, Notkins AL . The zinc-finger transcription factor INSM1 is expressed during embryo development and interacts with the Cbl-associated protein. Genomics 2002; 80: 54–61.
Lan MS, Li Q, Lu J, Modi WS, Notkins AL . Genomic organization, 5′-upstream sequence, and chromosomal localization of an insulinoma-associated intronless gene, IA-1. J Biol Chem 1994; 269: 14170–14174.
Li Q, Notkins AL, Lan MS . Molecular characterization of the promoter region of a neuroendocrine tumor marker, IA-1. Biochem Biophys Res Commun 1997; 236: 776–781.
Breslin MB, Zhu M, Lan MS . NeuroD1/E47 regulates the E-box element of a novel zinc finger transcription factor, IA-1, in developing nervous system. J Biol Chem 2003; 278: 38991–38997.
Li S, MacLaughlin FC, Fewell JG, Gondo M, Wang J, Nicol F et al. Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid. Gene Therapy 2001; 8: 494–497.
Park CW, Park YM, Lee GT, Lee Y, Woo S, Cha JY et al. Targeting of therapeutic gene expression to the liver by using liver-type pyruvate kinase proximal promoter and the SV40 viral enhancer active in multiple cell types. Biochem Biophys Res Commun 2004; 314: 131–137.
Yazawa K, Fisher WE, Brunicardi FC . Current progress in suicide gene therapy for cancer. World J Surg 2002; 26: 783–789.
Fillat C, Carrio M, Cascante A, Sangro B . Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003; 3: 13–26.
Nagalla SR, Spindel ER . Functional analysis of the 5′-flanking region of the human gastrin-releasing peptide gene in small cell lung carcinoma cell lines. Cancer Res 1994; 54: 4461–4467.
Graessmann M, Menne J, Liebler M, Graeber I, Graessmann A . Helper activity for gene expression, a novel function of the SV40 enhancer. Nucleic Acids Res 1989; 17: 6603–6612.
Dean DA . Import of plasmid DNA into the nucleus is sequence specific. Exp Cell Res 1997; 230: 293–302.
Dean DA, Dean BS, Muller S, Smith LC . Sequence requirements for plasmid nuclear import. Exp Cell Res 1999; 253: 713–722.
Young JL, Benoit JN, Dean DA . Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature. Gene Therapy 2003; 10: 1465–1470.
Mermod N, Williams TJ, Tjian R . Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature 1988; 332: 557–561.
Richards CA, Austin EA, Huber BE . Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995; 6: 881–893.
Pavelic K, Hrascan R, Kapitanovic S, Vranes Z, Cabrijan T, Spaventi S et al. Molecular genetics of malignant insulinoma. Anticancer Res 1996; 16: 1707–1717.
Cesen-Cummings K, Fernstrom MJ, Malkinson AM, Ruch RJ . Frequent reduction of gap junctional intercellular communication and connexin43 expression in human and mouse lung carcinoma cells. Carcinogenesis 1998; 19: 61–67.
Qiao J, Black ME, Caruso M . Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther 2000; 11: 1569–1576.
Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GL et al. Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85–92.
Ammerpohl O, Thormeyer D, Khan Z, Appelskog IB, Gojkovic Z, Almqvist PM et al. HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem Biophys Res Commun 2004; 324: 8–14.
Hansen LT, Lundin C, Helleday T, Poulsen HS, Sorensen CS, Petersen LN et al. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer 2003; 40: 157–164.
Acknowledgements
This work was supported by the Danish Cancer Society, the Danish Medical Research Council, the Danish Cancer Research Foundation, the Aase and Ejnar Danielsens Foundation and the AP Møller Foundation for the Advancement of Medical Science.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pedersen, N., Pedersen, M., Lan, M. et al. The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer. Cancer Gene Ther 13, 375–384 (2006). https://doi.org/10.1038/sj.cgt.7700887
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700887
Keywords
This article is cited by
-
Insulinoma-associated protein 1 (INSM1): a potential biomarker and therapeutic target for neuroendocrine tumors
Cellular Oncology (2020)
-
Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites
Endocrine Pathology (2019)
-
Insertion of a nuclear factor kappa B DNA nuclear-targeting sequence potentiates suicide gene therapy efficacy in lung cancer cell lines
Cancer Gene Therapy (2012)
-
Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas
Cancer Gene Therapy (2012)
-
Herpes simplex virus induces the marked up-regulation of the zinc finger transcriptional factor INSM1, which modulates the expression and localization of the immediate early protein ICP0
Virology Journal (2011)